Table 4 Clinical information for irAE group
No. | irAE | CTCAE grade | Onset date | Nivolumab line | Duration of treatment with nivolumab | Treatment | Outcome |
|---|---|---|---|---|---|---|---|
1 | Diarrhea/colitis | 1 | 60 | 5 | 228 | Symptomatic therapy | Improved |
Appetite loss | 2 | 158 | Â | Â | Â | Â | |
2 | Pruritus | 1 | 28 | 5 | 72 | Observation | Improved |
Edema limbs | 1 | 28 | Â | Â | Symptomatic therapy | Improved | |
QTc interval prolonged | 1 | 42 | Â | Â | Observation | Improved | |
3 | Type 1 DM/Hyperglycemia | 3 | 407 | 4 | 974 | Insulin injection + DPP4 inhibitor | Improved |
4 | Pruritus | 1 | 72 | 6 | 902 | Observation | Improved |
Hypothyroidism | 1 | 167 | Â | Â | Thyroid hormone | Improved | |
Type 1 DM/Hyperglycemia | 3 | 195 | Â | Â | Insulin injection | Improved | |
5 | Dry skin | 1 | 29 | 5 | 135 | Observation | Improved |
Diarrhea/colitis | 2 | 60 | Â | Â | Corticosteroid | Improved | |
6 | Diarrhea/colitis | 3 | 93 | 5 | 350 | Corticosteroid | Improved |
7 | Rash | 1 | 11 | 4 | 266 | Observation | Improved |
8 | Diarrhea/colitis | 1 | 33 | 3 | 140 | Observation | Improved |
9 | Peripheral motor neuropathy | 3 | 3 | 5 | 107 | Corticosteroid | Improved |
10 | Rash | 2 | 13 | 4 | 118 | Corticosteroid | Improved |
Diarrhea/colitis | 1 | 13 | Â | Â | Â | Â | |
11 | Adrenal insufficiency | 3 | 143 | 6 | 109 | Corticosteroid | Improved |
12 | Myalgia | 2 | 16 | 3 | 194 | Corticosteroid | Improved |
13 | AST increased | 3 | 28 | 3 | 147 | Observation | Improved |
ALT increased | 2 | 28 | Â | Â | Observation | Improved | |
14 | Pneumonitis | 3 | 32 | 4 | 63 | Corticosteroid | Stable |